ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,127.79
1.26%
US Tech 100
17,446.00
2.17%
Dow Jones
38,675.68
1.18%
Brent Oil
83.025
-0.12%
Bitcoin
63,764.17
-0.37%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Caribou Biosciences Inc (CRBU) Quote

Caribou Biosciences Inc

Caribou Biosciences Inc (CRBU)

Amd Commo Exagr
3.77
0.13
(3.57%)
Closed May 05 4:00PM
Delayed by 15 minutes
3.73
-0.04
(-1.06%)
After Hours: 7:33PM
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
3.73
Bid
3.70
Ask
8.99
Volume
1,817,389
3.69 Day's Range 3.90
3.44 52 Week Range 8.5899
Market Cap
339.583M
Previous Close
3.64
Open
3.77
Last Trade
50
@
3.7
Last Trade Time
Financial Volume
$ 6,850,037
VWAP
3.7692
Average Volume (3m)
1,618,415
Shares Outstanding
90,314,501
Dividend Yield
-
PE Ratio
-3.33
Earnings Per Share (EPS)
-1.13
Revenue
34.48M
Net Profit
-102.07M

About Caribou Biosciences Inc

Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies.

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.cariboubio.com
Headquarters
Dover, Delaware, USA
Founded
1970
Caribou Biosciences Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker CRBU. The last closing price for Caribou Biosciences was $3.64. Over the last year, Caribou Biosciences shares have traded in a share price range of $ 3.44 to $ 8.5899.

Caribou Biosciences currently has 90,314,501 shares outstanding. The market capitalization of Caribou Biosciences is $339.58 million. Caribou Biosciences has a price to earnings ratio (PE ratio) of -3.33.

CRBU Latest News

More News

Caribou Biosciences to Participate in Upcoming Investor Conferences

BERKELEY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the...

May 01 2024
GlobeNewswire Inc.

Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

BERKELEY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two...

April 24 2024
GlobeNewswire Inc.

Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

BERKELEY, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced an...

April 15 2024
GlobeNewswire Inc.

Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus

-- FDA has cleared Caribou’s IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 -- -- Driven by encouraging initial...

April 04 2024
GlobeNewswire Inc.

Form S-8 - Securities to be offered to employees in employee benefit plans

March 11 2024
Edgar (US Regulatory)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

March 11 2024
Edgar (US Regulatory)

Form 8-K - Current report

March 11 2024
Edgar (US Regulatory)

Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

-- 30th patient dosed in CB-010 ANTLER Phase 1 trial dose expansion; initial dose expansion data and RP2D to be disclosed in Q2 2024 -- -- 1st patient dosed in CB-012 AMpLify Phase 1 trial for...

March 11 2024
GlobeNewswire Inc.

Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting

BERKELEY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that...

March 05 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

February 22 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.17-4.358974358973.93.93.5616166213.68356481CS
4-0.88-19.08893709334.614.6653.5615554054.00734291CS
12-3.13-45.62682215746.868.333.5616184155.37302032CS
26-0.03-0.7978723404263.768.333.5616706565.47835597CS
52-0.5-11.82033096934.238.58993.4419629915.6390174CS
156-13.92-78.866855524117.6532.6453.4411150797.98158664CS
260-13.92-78.866855524117.6532.6453.4411150797.98158664CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BENFBeneficient
$ 6.8001
(254.17%)
31.01M
SGBXSafe and Green Holdings Corporation
$ 5.49
(87.37%)
92.18M
SHOTWSafety Shot Inc
$ 0.45
(45.16%)
644
AIPArteris Inc
$ 8.185
(38.03%)
1.11M
RGFReal Good Food Company Inc
$ 0.85
(37.32%)
4.26M
MNDRMobile health Network Solutions
$ 3.33
(-84.91%)
18.76M
NUVOHoldco Nuvo Group DG Ltd
$ 2.00
(-57.54%)
1.04M
SPTSprout Social Inc
$ 28.82
(-40.15%)
13.47M
UNITUniti Group Inc
$ 4.441
(-26.35%)
21.07M
IPDNProfessional Diversity Network Inc
$ 1.29
(-24.12%)
662.59k
AAPLApple Inc
$ 183.38
(5.98%)
163.22M
SQQQProShares UltraPro Short QQQ
$ 11.08
(-5.94%)
154.59M
JAGXJaguar Health Inc
$ 0.3164
(7.91%)
142.47M
NKLANikola Corporation
$ 0.6526
(6.55%)
106.88M
SGBXSafe and Green Holdings Corporation
$ 5.49
(87.37%)
92.18M

CRBU Discussion

View Posts
Monksdream Monksdream 1 week ago
CRBU under $5
👍️0
stocksrising stocksrising 2 months ago
It seemed like they were running on all positive cylinders, but must have blown a gasket at current Conference/ Fireside???
👍️0
Monksdream Monksdream 6 months ago
CRBU new 52 week low
👍️0
jondoeuk jondoeuk 10 months ago
Yes, with both drugs still in development. As for CRBU, they gave an update (plus public offering) https://finance.yahoo.com/news/caribou-biosciences-reports-positive-clinical-200100822.html https://investor.cariboubio.com/static-files/d818ed1a-aea2-41c1-84ea-bd05a4276cbb

Personally, there seem to be red flags, such as no expansion/persistence data. I know they give huge amounts of LD chemo, higher (I think) than anyone else, which could be generating responses, explaining why there is no dose response.
👍️0
trueblue trueblue 10 months ago
.
👍️0
trueblue trueblue 10 months ago
$23.00 price target! Now that is a good start!! Glad I loaded up! Jmo
👍️0
NY1972 NY1972 10 months ago
Didn't they buy TRIL? Just gambling with billions from US government.
👍️0
jondoeuk jondoeuk 10 months ago
PFE is very selective in who they fund https://finance.yahoo.com/news/caribou-biosciences-announces-25-million-120000433.html
👍️0
trueblue trueblue 10 months ago
Great day in my accounts again! Really liking my CRBU shares! Jmo holding for the long haul!!
👍️0
Monksdream Monksdream 10 months ago
CRBU now No 9 on the Barchart Top 10
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0
trueblue trueblue 10 months ago
Added to my existing shares today, I bought shares months ago. I like Crbu a crisper company! Looks like Pfizer does also! Jmo
👍️0
Stockexpertpro Stockexpertpro 10 months ago
CRBU Loss 108 Million Dollars Company only has preclinical and phase 1 in its pipeline company is Years away from having anything if ever did a stock offering at 5.33$ for 25 Million thats only 1 QTR Cash burn for this company Sell the News https://www.cariboubio.com/pipeline/
👍️0
TheFinalCD TheFinalCD 10 months ago
CRBU= JUST WOW

https://finviz.com/quote.ashx?t=CRBU&ty=c&ta=1&p=d
👍️0
Monksdream Monksdream 10 months ago
CRBU No 1 on the early Barchart Top 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0

Your Recent History

NASDAQ
CRBU
Caribou Biosciences
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved